Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice.
Ontology highlight
ABSTRACT: Adeno-associated virus (AAV) vector-based gene therapies can be applied to a wide range of diseases. AAV expression can last for months to years, but vector re-administration may be necessary to achieve life-long treatment. Unfortunately, immune responses against these vectors are potentiated after the first administration, preventing the clinical use of repeated administration of AAVs. Reducing the immune response against AAVs while minimizing broad immunosuppression would improve gene delivery efficiency and long-term safety. In this study, we quantified the contributions of multiple immune system components of the anti-AAV response in mice. We identified B-cell-mediated immunity as a critical component preventing vector re-administration. Additionally, we found that IgG depletion alone
SUBMITTER: Chen M
PROVIDER: S-EPMC10183056 | biostudies-literature | 2023 May
REPOSITORIES: biostudies-literature
ACCESS DATA